Artificial intelligence in COVID-19 drug repurposing

By Yadi Zhou, Fei Wang, Jian Tang, Ruth Nussinov, Feixiong Cheng. The Lancet Digital Health, 2020

413 citations recorded by the source corpus.

Drug repurposing or repositioning is a technique whereby existing drugs are used to treat emerging and challenging diseases, including COVID-19. Drug repurposing has become a promising approach because of the opportunity for reduced development timelines and overall costs. In the big data era, artificial intelligence (AI) and network medicine offer cutting-edge application of information science to defining disease, medicine, therapeutics, and identifying targets with the least error. In this Review, we introduce guidelines on how to use AI for accelerating drug repurposing or repositioning, for which AI approaches are not just formidable but are also necessary. We discuss how to use AI models in precision medicine, and as an example, how AI models can accelerate COVID-19 drug repurposing. Rapidly developing, powerful, and innovative AI and network medicine technologies can expedite therapeutic development. This Review provides a strong rationale for using AI-based assistive tools for drug repurposing medications for human disease, including during the COVID-19 pandemic.

Subfields: Computational Theory and Mathematics, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/fbfb51efec92da9731e810923371c436d5226b2f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Computational Theory and Mathematics

Citations in the corpus

Artificial intelligence in cancer target identification and drug discovery (2022, methodology): “The key to identify therapeutic targets and discover drugs using ML-based biology analysis is to make use of network features in biological networks.”
Artificial intelligence in drug development (2025, positive): “An advanced pipeline has been created that integrates multimodal datasets, generates molecular leads using AI, ranks them by efficacy and safety, and uses deep reinforcement learning to create patentable analogs for testing 212 .”